Needham & Company Maintains an 'Underperform' on Immunogen (IMGN); Broad but Still Risky Plans for T-DM1 and Pipeline, Solid Cash Position, & Lack of 2011 Milestones
Tweet Send to a Friend
Needham & Company maintains an 'Underperform' on Immunogen Inc. (NASDAQ: IMGN).
Needham analyst says, "We believe the current valuation is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "We believe the current valuation is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
